Triple‐Dose Versus Single‐Dose Gadoteridol in Multiple Sclerosis Patients

Nine patients with multiple sclerosis underwent brain magnetic resonance imaging (MRI) to evaluate the contrast enhancement of individual lesions after a single dose and a triple dose of gadolinium. A single dose (0.1 mmol/kg) of gadoteridol was administered and after a delay, axial T1‐weighted images were obtained. After an additional 0.2‐mmol/kg dose, the same T1‐weighted sequence was repeated. An unblinded reader simultaneously viewed the images from both doses, and utilizing a computer console to rule out flow artifacts, created a gold standard of “definite” enhancing lesions. Using this system, he determined that there was a total of 12 definite enhancing lesions among the patients. This reader also evaluated lesion conspicuity. The contrast‐noise ratio was calculated for each lesion. A second reader, blinded to the dose used, then evaluated the number of enhancing lesions at both doses. The unblinded reader noted increased lesion conspicuity after the triple dose. Contrast‐noise ratios were significantly (p < 0.001) higher after the triple dose (mean, 9.19) than after the single dose (mean, 2.97). The blinded reader detected 11 of the 12 definite lesions on MRis after the triple dose (sensitivity, 92 %) but saw only 6 on MRis after the single dose (sensitivity, 50%). The difference was significant (p < 0.001 ). Subjective analysis of the films revealed an increase in “ghosting artifacts” at the high dose. Administration of tripledose gadolinium provides increased lesion conspicuity and an improved lesion detection rate when compared to single‐dose gadolinium in patients with multiple sclerosis.

[1]  N. Patronas,et al.  Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing‐remitting multiple sclerosis: Implications for clinical trials and natural history , 1991, Annals of neurology.

[2]  F. Barkhof,et al.  Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. , 1992, AJR. American journal of roentgenology.

[3]  J. Valk,et al.  Contrast Enhanced Magnetic Resonance Imaging of the Brain Using Gadolinium-DTPA , 1987, Acta radiologica.

[4]  B E Kendall,et al.  Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. , 1988, Brain : a journal of neurology.

[5]  R. Raininko,et al.  Value of High Contrast Medium Dose in Brain CT , 1982, Journal of computer assisted tomography.

[6]  A. Detsky,et al.  The Accuracy of Magnetic Resonance Imaging in Patients With Suspected Multiple Sclerosis , 1993 .

[7]  W. I. McDonald,et al.  Heterogeneity of blood‐brain barrier changes in multiple sclerosis , 1990, Neurology.

[8]  D. Pelz,et al.  CT of multiple sclerosis: reassessment of delayed scanning with high doses of contrast material. , 1985, AJR. American journal of roentgenology.

[9]  B E Kendall,et al.  Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. , 1990, Brain : a journal of neurology.

[10]  K. Davis,et al.  Expanded high iodine dose in computed cranial tomography: a preliminary report. , 1979, Radiology.

[11]  V. Runge,et al.  High‐dose applications of gadolinium chelates in magnetic resonance imaging , 1991, Magnetic resonance in medicine.

[12]  H T Mount,et al.  Multiple sclerosis and other demyelinating diseases. , 1973, Canadian Medical Association journal.

[13]  V. Runge,et al.  High‐dose gadoteridol in MR imaging of intracranial neoplasms , 1992, Journal of magnetic resonance imaging : JMRI.

[14]  J. Ehrhardt,et al.  Review of the use of high-dose gadoteridol in the magnetic resonance evaluation of central nervous system tumors. , 1992, Investigative radiology.

[15]  W. Kaiser,et al.  Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. , 1993, Radiology.

[16]  D. N. Landon,et al.  Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. , 1990, Brain : a journal of neurology.

[17]  B E Kendall,et al.  The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. , 1991, Brain : a journal of neurology.

[18]  F. Roncaroli,et al.  Neuropathology of multiple sclerosis , 2012 .